To Top
  1. Establishing Specialized CDMO Capabilities for the Production of Advanced Therapies
    Oliver Technow, President of BioVectra, explains the necessity of forward-thinking CDMOs.
  2. BioPharma CDMO Success Requires Technical Leadership and Problem-Solving Capabilities

    As more antibody and other advanced therapies reach the commercialization stage, branded biologic and biosimilar development companies are increasingly turning to outsourcing partners, explains Federico Pollano, Senior Vice President Business Development for Rentschler Biotechnologie GmbH.

  3. Building a Robust Supply Chain with Dependable Quality Primary Suppliers

    Drug manufacturers and their suppliers face a number of challenges, such as downward pricing pressures and the need for flexibility and speed to market, says Dale Martin, General Manager & CFO for CapsCanada.

  4. Meeting Biopharma Contract Manufacturing Needs with a Flexible Global Network

    Gustavo Mahler, President & CEO of AGC Biologics discusses the increasing need for CDMO support to provide with advanced capabilities and technology platforms across scales and geographies. 

    President & CEOAGC Biologics
  5. Creating Value with Tailored ODT Solutions

    Graeme MacLeod, Global Technical Development Manager at SPI Pharma, explains the benefits of ODT dosage forms.

  6. Driving Change in the Pharma Industry and Biotech One Relationship at a Time

    Syed T. Husain, Chief Commercial Officer and Catherine Hanley, Head of Marketing & Corporate Communications at Alcami Corporation discuss changing the industry’s mindset through relationships.

  7. The Global Wearable Robotic Exoskeleton Market is Projected to Reach $5.4 Billion by 2028

    The wearable exoskeleton market is projected to grow at a CAGR of 43.48%, during the forecast period from 2018 to 2028.

  8. Pillar Biosciences Enters Strategic Partnership with China Biotech Services Holdings to Deliver Precision Diagnostics to Markets in Asia

    Under the terms of the agreement, Pillar Biosciences will create a joint venture company with CBSH's subsidiary Central Laboratory (Holdings) Limited to provide precision diagnostic products and services to Hong Kong, Macau, South Korea and Southeast Asia. 

  9. Fujifilm Announces the Launch of Its Next Generation Apollo™ X Advanced Mammalian Expression System

    Titres achieved are in excess of 10g/L without compromising product quality.

  10. SightGlass Vision Multicenter Trial to Study Novel Eyeglasses to Control Nearsightedness for FDA Approval

    CYPRESS currently enrolling children aged 6-9 at clinical sites throughout the U.S. and Canada.

     

  11. Focused on Fermentation

    Capua BioServices continues to invest to support modern fermentation, explains Elise Mous Director Sales & Marketing/Business Development and Thomas De Maria, Business Development Manager.

  12. People, Expertise and Dedication are Key to Successful Strategic Partnerships

    People and expertise drive the success of strategic partnerships, according to Elise Mous, Director of Sales & Marketing/Business Development at Capua Bioservices.

  13. The Coming of Age of Amorphous Solid Dispersions

    Márcio Temtem, Director for Drug Product Development at Hovione, discusses drug formulation using amorphous solid dispersions.

  14. Procuring Equipment at the Speed of Business

    Your equipment is the backbone of your entire facility, explains Adam Covitt, Vice President of Federal Equipment Company.

  15. Hard-Shell Capsule Solutions for Sensitive Compounds: A Focus on Probiotics

    Eli Elias, Director of Business Development for CapsCanada explains why hard-shell capsules designed to degrade under specific conditions are a better option for probiotics.

  16. Fully Supporting Customer Needs for Biologics Development and Manufacturing

    James Park, Senior Vice President and Global Head, Business Development Center for Samsung BioLogics discusses the construction of three state-of-the-art production facilities in the last seven years.

  17. New Assays for Detecting Genomic Mutations Launched by Contextual Genomics

    Hotspot assays detect genomic mutations in blood and solid tumors.

  18. Initial Positive Results Lead to Expanded Cancer Trial
    Deciphera Pharmaceuticals expands clinical trial for advanced malignancies to include patients with tenosynovial giant cell tumors (TGCTs).
  19. Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets

    Biogen made a one-time upfront $74 million payment to Skyhawk for research services and an exclusive license to therapeutic candidates for multiple sclerosis, spinal muscular atrophy and other neurological diseases to be developed using Skyhawk's SkySTAR™ platform.

  20. AstraZeneca Announces Organizational Changes

    José Baselga, MD, PhD, appointed to head R&D for Oncology.

      

Nice Insight Awareness/Perception Scorecard

Research. Compare. Contact. Find the Ideal Partner.

Customer Awareness (CA) describes a buyer’s knowledge of your offering, while Customer Perception (CP) describes how a buyer rates your company based on that knowledge. Nice Insight’s CA/CP scorecard allows you to measure market awareness and perception of you and your industry peers based on acknowledged outsourcing drivers.

  1. Search by company type, region, market segment and services.
  2. Select up to 5 companies to compare.
  3. View CA & CP performance scores against industry benchmark ratings.
SEARCH COMPANIES
Drug Development

Addressing the Challenges and Opportunities Presented by Advanced Therapies

Jan 15, 2019 5:09:05 PM PAO-M01-19-NI_CL-001
Drug Development

Researchers Identify Potential Approach for Treating the Toughest Breast Cancer

Jan 9, 2019 4:13:58 PM PAO-M01-19-NI-013
Immuno-oncology

Sanofi and Regeneron Immuno-oncology Collaboration Ending

Jan 9, 2019 2:43:05 PM PAO-M01-19-NI-012
Investment

Swiss AI Firm Raises Funds for Entry into U.S.

Jan 9, 2019 2:39:22 PM PAO-M01-19-NI-011
R&D

Allergan Establishes R&D Group in Massachusetts

Jan 9, 2019 2:32:28 PM PAO-M01-19-NI-010
Inhalation

FDA Approves First Inhaler with Built-in Sensors

Jan 9, 2019 2:27:00 PM PAO-M01-19-NI-009
Investment

Antengene Benefits from Second-Round Financing

Jan 8, 2019 11:10:49 AM PAO-M01-19-NI-008
Investment

Biotech Company Stealth BioTherapeutics Files for IPO

Jan 8, 2019 11:05:35 AM PAO-M01-19-NI-007
Clinical Trials

Initial Positive Results Lead to Expanded Cancer Trial

Jan 8, 2019 11:00:42 AM PAO-M01-19-NI-006
Cell and Gene Therapy

New Assays for Detecting Genomic Mutations Launched by Contextual Genomics

Jan 8, 2019 10:58:34 AM PAO-M01-19-NI-005
Investment

Vedanta Increases Investment

Jan 8, 2019 10:55:28 AM PAO-M01-19-NI-004
Drug Pricing

Drug Companies Raise Prices to Start New Year

Jan 8, 2019 10:51:10 AM PAO-M01-19-NI-003
FDA Approval

FDA Approves Parkinson’s Drug

Jan 8, 2019 10:45:34 AM PAO-M01-19-NI-002
Immuno-oncology

Gilead Invests in Immuno-oncology

Jan 3, 2019 4:55:00 PM PAO-M01-19-NI-001
Columns

Nice Insight Overview

The Evolution of Pharma Depends on Data Integration and Application
New business models must be adopted to leverage the massive amounts of data generated across the pharma/healthcare continuum.

Roundtable

Q: What Innovative Technologies Had the Greatest Impact on your Company this Year? What Were the Impacts?

New Drug News

Regulatory Approval Brings siRNA into the Rare Disease Toolbox
David Alvaro, Ph.D., Scientific Editorial Director, Nice Insight

Regulatory Spotlight

FDA Delays Enforcement of Serialization Mandate

KshitiJ (TJ) Ladage, Market Research Manager, Nice Insight